The percentage of the dose per gram of the organ (% gram/tissue: % dose/organ/mass in grams) was decided for each sample

The percentage of the dose per gram of the organ (% gram/tissue: % dose/organ/mass in grams) was decided for each sample. == Statistics == All results were reported as mean and SD of at least three replicates, unless stated otherwise. mucus of nanoparticles were determined. The nanoparticle nasal toxicity was evaluated in vitro using RPMI 2651 nasal cell lines. Finally, in festn biodistribution was assessed by gamma scintigraphy via Tc99m labeling from the particles. == Results == Among the different types of nanoparticles produced, the SVT-LCN_MaiLab showed the most ideal physicochemical characteristics, with small diameter (200 nm), positive surface demand (+48 mV) and high encapsulation efficiency (EE; 98%). Size distribution was further confirmed by nanoparticle tracking analysis and electron microscopy. The particles showed a relatively fast release of simvastatin in vitro (35. 6%4. 2% in 6 hours) in simulated nasal fluid. Blank nanoparticles did not show cytotoxicity, evidencing that the formulation is safe intended for nasal supervision, while cytotoxicity of simvastatin-loaded nanoparticles (IC50) was found to be three times lower than the drug answer (9. 92 vs a few. 50 M). In rats, a significantly higher radioactivity was evidenced in the brain after nasal delivery of simvastatin-loaded nanoparticles in comparison to the supervision of a similar dose of simvastatin suspension. == Summary == The SVT-LCNs developed presented some of the most desirable characteristics for mucosal delivery, that is, small particle size, positive surface demand, long-term stability, high EE, and mucoadhesion. In addition , they displayed two exciting features: First was their biodegradability by D609 enzymes present in the mucus layer, such as lysozyme. This indicates a new Trojan-horse strategy which may enhance drug release in the proximity of the nasal mucosa. Second was their ability to enhance the nose-to-brain transport as evidenced by preliminary gamma scintigraphy studies. Keywords: nose-to-brain, simvastatin, nanoparticles, neurodegenerative diseases, gamma scintigraphy, small-angle X-ray scattering (SAXS), lysozyme, biodegradable nanoparticles == Intro == The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are arguably among the biggest advances in cardiovascular treatment in the 20th century. Statins reduce cholesterol serum levels by reversibly inhibiting HMG-CoA reductase, an essential enzyme in cholesterol biosynthesis, reducing the risk of serious cardiovascular events. 1, 2Along with their lipid-lowering effects, statins have been credited for a range of results or pleiotropic effects. 3The mechanisms by which pleiotropic results occur are diverse and still not fully elucidated. Many of those effects are attributed to the inhibition of isoprenoid intermediates, that is, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, and their downstream effects on intracellular signaling proteins Ras, Rho, and Rac. 4Pleiotropic effects of statins include anti-inflammatory, antioxidant, immunomodulatory, and antithrombotic actions as well as the ability to stabilize atherosclerotic plaques and inhibit the proliferation of vascular smooth muscle. 57Because of these pleiotropic effects, it is now believed that statins could be more widely employed in other diseases, such as rheumatoid arthritis, COPD, cancer, and neurodegenerative disorders. 811 In the case of Alzheimers disease, clinical research evidenced that an increase in brain cholesterol levels directly upregulates the production of -amyloid protein, the major protein involved in the formation of senile plaques in the brain of Alzheimers patients. 12, 13Moreover, the most widely recognized risk D609 element of late-onset Alzheimers is the genetic variance in a transporter of cholesterol called apolipoprotein E 4 which supposedly alters the brain cholesterol homeostasis, leading to Alzheimers disease development. 14, 15The inhibition of brain cholesterol synthesis has been shown to reduce -amyloid accumulation, interfering with the production of -amyloid and its accumulation as extracellular plaques. 16, 17These works suggest that the effects of statins in lowering the cholesterol levels may have a beneficial role on the pathogenesis of Alzheimers disease. It has also been postulated that statin pleiotropic effects could provide further benefit to Alzheimers patients via modulation from the chronic inflammatory response, another key factor in neurodegenerative process. 11However, these effects of statins are only seen at high therapeutic concentrations at the target organ, and they are difficult to be observed when the conventional oral supervision route is selected. In fact , statins undergo extensive first-pass metabolism, and their hydrophilic metabolites are prevented from Rabbit Polyclonal to ARMX3 crossing D609 the bloodbrain barrier (BBB), the principal biological barrier protecting the central nervous system D609 (CNS). 3Despite the fact that statins are generally well tolerated, this drug class has been associated with some undesirable events, in particular myopathy. This side effect can be severe and progress to rhabdomyolysis, to the point that cerivastatin was withdrawn from the market.